相关实验视频

Updated: May 7, 2026

Nutrient Regulation by Continuous Feeding for Large-scale Expansion of Mammalian Cells in Spheroids

Nutrient Regulation by Continuous Feeding for Large-scale Expansion of Mammalian Cells in Spheroids

Published on: September 25, 2016

乳腺生物反应器的建造和识别,用于人类衍生的低血糖蛋白氨酸

Kongwei Huang¹, Xiuying Yan¹, Zhipeng Li²

¹Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, School of Life Science and Engineering, Foshan University, Foshan 528225, China.

Life (Basel, Switzerland)

|February 24, 2024

概括

研究人员开发了转基因小鼠,以在牛奶中产生人类氨酸. 这种牛奶显示了未来通过口服氨酸的管理来治疗糖尿病的潜力,在小鼠中没有观察到任何不良影响.

科学领域:

生物技术是生物技术.
哺乳动物遗传学哺乳动物遗传学
代谢工程是代谢工程.

背景情况:

哺乳动物的乳腺自然产生生物活性蛋白质.
人类氨酸是一种参与葡萄糖调节的类激素.
开发新的糖尿病治疗策略是全球卫生优先事项.

研究的目的:

设计一种转基因乳腺生物反应器,用于在家禽中生产人类氨酸.
评估在小鼠牛奶中生产人类氨酸的可行性和安全性.
为了研究消费氨酸强化牛奶的生理影响.

主要方法:

Prokaryotic 微注射被用于创建转基因小鼠.
使用逆转录聚合酶链反应 (RT-PCR) 和定量PCR (qPCR) 确认了基因表达.
蛋白质的存在和产量通过西式涂抹和酶相关免疫吸收试验 (ELISA) 得到验证.

主要成果:

转基因小鼠成功地在他们的牛奶中产生了人类氨酸,产量约为1.44μg/mL.
摄入氨酸强化牛奶导致食物摄入量,血糖和葡萄糖耐受性的变化微不足道.
在涉及脂肪酸代谢的特定便微生物菌株的丰度中观察到显著的变化.

结论:

转基因小鼠作为一种可行的模型,可以在牛奶中生产人类的氨基氨酸.
口服氨酸强化牛奶在小鼠中显示出安全性.
这种方法提供了一种潜在的新策略,可以通过基于牛奶的氨酸输送来管理糖尿病症状.

关键词:

艾米林氨基酸是什么?糖尿病糖尿病患者糖尿病患者乳腺生物反应器乳腺生物反应器转基因组学是指转基因组学.

更多相关视频

Pancreatic Tissue-Derived Extracellular Matrix Bioink for Printing 3D Cell-Laden Pancreatic Tissue Constructs

Pancreatic Tissue-Derived Extracellular Matrix Bioink for Printing 3D Cell-Laden Pancreatic Tissue Constructs

Published on: December 13, 2019

Computational Reconstruction of Pancreatic Islets as a Tool for Structural and Functional Analysis

Computational Reconstruction of Pancreatic Islets as a Tool for Structural and Functional Analysis

Published on: March 9, 2022

相关概念视频

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...